[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100450181":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":33,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient",null,"Patient satisfaction with end of life care. Questionnaire to be completed at baseline and every 8 week.",[13],"Other: Questionaire",{"label":15,"type":10,"description":16,"interventionNames":17},"Carer","Carer satisfaction with care leading up to the time of death and the quality of the patient's death. Questionnaire to be completed at baseline and every 8 weeks,and 5-7 weeks after patient deceased.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Questionaire","Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.\n\nCarer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying.",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Kristina Lindemann, MD, PhD","CONTACT","004722934983","klinde@ous-hf.no",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Sanne Nygaard Lindberg, MSc","004535453398","sanne.nygaard.lindberg@regionh.dk",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Norwegian Radium Hospital","RECRUITING","Oslo","0310","Norway","NO",{"type":42,"coordinates":43},"Point",[44,45],10.74609,59.91273,{"lat":45,"lon":44},[48,51],{"name":25,"role":26,"phone":49,"phoneExt":50,"email":28},"+47 22934000","5690",{"name":25,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[56],{"name":57,"class":6},"Australia New Zealand Gynaecological Oncology Group","100450181","palliation-in-gynae-oncology-patients-expectations-and-assessment-of-care-peace-100450181",false,"NCT05142150","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care","PEACE","Inclusion Criteria:\n\nA patient will be eligible for inclusion only if all of the following criteria are fulfilled:\n\n1. Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician\\*. Potential patient groups include, but are not limited to, those with platinum-resistant\u002Frefractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic\u002Frecurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade\u002Fundifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.\n2. Patients may be on active cancer treatment, about to commence active cancer treatment or under observation\u002Fpalliative care.\n3. Age ≥ 18 years\n4. Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol.\n2. A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.\n3. Participation in another clinical trial.\n\nA patient will be asked to appoint a carer.\n\nInclusion criteria carer:\n\n1. Age ≥ 18 years\n2. A relative or close friend who is actively supporting the patient in her illness\n3. Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion criteria carer\n\nA carer will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol\n2. A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.","FEMALE","18 Years",{"count":69,"type":70},73,"ESTIMATED","6 Weeks","OBSERVATIONAL","The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.",[75],"Gynaecological Cancer","2024-09-27",{"date":78,"type":79},"2024-10-01","ACTUAL",{"date":81,"type":79},"2023-01-12",{"date":83,"type":70},"2027-12-31",{"name":5,"class":6},1]